

# **Poliomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/P41BB181D1DEEN.html>

Date: December 2022

Pages: 94

Price: US\$ 2,000.00 (Single User License)

ID: P41BB181D1DEEN

## **Abstracts**

Poliomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Drugs In Development, 2022, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players

involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 5, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 2, 3 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Poliomyelitis - Overview
- Poliomyelitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Poliomyelitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Poliomyelitis - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Bharat Biotech Ltd
- Biken Co Ltd
- Biological E Ltd
- Biological Mimetics Inc
- Boryung Pharmaceutical Co Ltd
- CanSino Biologics Inc
- Grifols SA
- Helix Biogen Institute
- Intravacc BV
- Johnson & Johnson
- KM Biologics Co Ltd
- LG Chem Ltd
- Micron Biomedical Inc
- Nanolek
- Panacea Biotec Ltd
- Serum Institute of India Pvt Ltd
- Shantha Biotechnics Pvt Ltd
- Statera Biopharma Inc
- Vaxxas Inc
- Wuhan Institute of Biological Products Co Ltd

**Poliomyelitis - Drug Profiles**

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile

Product Description

Mechanism Of Action

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile

Product Description

Mechanism Of Action

(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

**BK-1310 - Drug Profile**

Product Description

Mechanism Of Action

**CSB-017 - Drug Profile**

Product Description

Mechanism Of Action

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

**JNJ-2348 - Drug Profile**

Product Description

Mechanism Of Action

KD-2396 - Drug Profile

Product Description

Mechanism Of Action

KD-370 - Drug Profile

Product Description

Mechanism Of Action

LBVC - Drug Profile

Product Description

Mechanism Of Action

LBVD - Drug Profile

Product Description

Mechanism Of Action

polio (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [serotype 1] vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [serotype 2] vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [serotype 2] vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

polio [serotype 3] (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [serotype 3] vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [serotype 3] vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [serotypes 1, 2, 3] vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [strain Sabin] vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [strain Sabin] vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [strain Sabin] vaccine - Drug Profile

Product Description

Mechanism Of Action

polio [strain Sabin] vaccine - Drug Profile

Product Description

Mechanism Of Action

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

polio vaccine - Drug Profile

Product Description

Mechanism Of Action

polio vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

poliomyelitis (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

poliomyelitis [sabin] (vero cell) vaccine - Drug Profile

Product Description

Mechanism Of Action

poliomyelitis [serotype PV3] (virus like particles) vaccine - Drug Profile

Product Description



Mechanism Of Action

poliomyelitis vaccine - Drug Profile

Product Description

Mechanism Of Action

poliomyelitis vaccine - Drug Profile

Product Description

Mechanism Of Action

poliomyelitis vaccine + rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

SA-702 - Drug Profile

Product Description

Mechanism Of Action

Poliomyelitis - Dormant Projects

Poliomyelitis - Discontinued Products

Poliomyelitis - Product Development Milestones

Featured News & Press Releases

Jun 09, 2022: Sinovac Biotech receives WHO prequalification for polio vaccine

Apr 12, 2022: Pertussis, Diphtheria, Tetanus, Polio, Hib vaccine filed in Japan: BIKEN/Mitsubishi

Apr 11, 2022: Notification of manufacturing and marketing approval application for pertussis/diphtheria/tetanus/inactivated polio/Hib combined vaccine (BK1310/MT-2355)

Apr 11, 2022: Marketing authorization application of pertussis, diphtheria, tetanus, inactivated polio and Hib combined vaccine (BK1310/MT-2355)

Jul 20, 2021: Intravacc's inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China

Dec 09, 2020: New polio vaccine against strain that threatens eradication is safe and generates immune response in adults, young children, and infants

Apr 23, 2020: AJ Vaccines secures WHO Prequalification for polio vaccine Picovax

Apr 16, 2019: Sinovac announces positive results from Phase III trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) published in the journal of Infectious Diseases

Mar 11, 2019: LG Chem gets \$33.4 mil. from Gates Foundation for vaccine development

May 21, 2018: A single-injection vaccine for the polio virus

Apr 19, 2018: Sinovac Announces Preliminary Results of Phase III Trial on sIPV

Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate

Sep 16, 2014: Vaxxas initiates research project on advancing next generation technology for polio vaccine delivery

Oct 31, 2012: Statens Serum Institut receives a grant of \$158,739 from Bill & Melinda Gates Foundation

Gates Foundation  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Poliomyelitis, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Companies, 2022 (Contd..1)  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022  
Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022  
Poliomyelitis - Pipeline by Bharat Biotech Ltd, 2022  
Poliomyelitis - Pipeline by Biken Co Ltd, 2022  
Poliomyelitis - Pipeline by Biological E Ltd, 2022  
Poliomyelitis - Pipeline by Biological Mimetics Inc, 2022  
Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, 2022  
Poliomyelitis - Pipeline by CanSino Biologics Inc, 2022  
Poliomyelitis - Pipeline by Grifols SA, 2022  
Poliomyelitis - Pipeline by Helix Biogen Institute, 2022  
Poliomyelitis - Pipeline by Intravacc BV, 2022  
Poliomyelitis - Pipeline by Johnson & Johnson, 2022  
Poliomyelitis - Pipeline by KM Biologics Co Ltd, 2022  
Poliomyelitis - Pipeline by LG Chem Ltd, 2022  
Poliomyelitis - Pipeline by Micron Biomedical Inc, 2022  
Poliomyelitis - Pipeline by Nanolek, 2022  
Poliomyelitis - Pipeline by Panacea Biotec Ltd, 2022  
Poliomyelitis - Pipeline by Serum Institute of India Pvt Ltd, 2022  
Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, 2022  
Poliomyelitis - Pipeline by Statera Biopharma Inc, 2022  
Poliomyelitis - Pipeline by Vaxxas Inc, 2022  
Poliomyelitis - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022  
Poliomyelitis - Dormant Projects, 2022  
Poliomyelitis - Dormant Projects, 2022 (Contd..1)

## Poliomyelitis - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Poliomyelitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Poliomyelitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P41BB181D1DEEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P41BB181D1DEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

